Keith Manchester
DirectoratRoivant Sciences· In proxies 2022–2024
Keith Manchester sits on 6 public boards.
Boards1
- Roivant SciencesDirector · 10 yr on the boardIndependentAudit—Paid as an executive
%20scale(0.100000,-0.100000)'%20fill='%23000000'%20stroke='none'%3e%3cpath%20d='M3195%205489%20c-380%20-49%20-706%20-317%20-831%20-682%20-56%20-163%20-54%20-112%20-54%20-1773%20l0%20-1534%20590%200%20590%200%200%201465%200%201465%20600%200%20600%200%200%20535%200%20535%20-712%20-1%20c-392%20-1%20-744%20-6%20-783%20-10z'/%3e%3c/g%3e%3c/svg%3e)
Board seats come from each company's latest proxy statement.
Experience
- Roivant SciencesPublic company · 4 yr
- Director2022 – Present · 4 yrStock in role +356%
- Arbutus BiopharmaPublic company · 3 yr
- Director2023 – Present · 3 yrNo stock prices for these years
- Arbutus Biopharma CorporationPublic company
- Director? – PresentNo stock prices for these years
- Kriya TherapeuticsPublic company
- Director? – PresentNo stock prices for these years
- Medigene AGPublic company
- Director? – PresentNo stock prices for these years
- Myovant Sciences Ltd.Public company
- Director? – PresentNo stock prices for these years
Roles come from the proxy statements of each company.
Activity
No new filings about this person in the feed.
Two people shown as one, or a wrong number?